NCT00603356 - Phase I Study of OSI-930 and Erlotinib in Cancer Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

July 31, 2010

Conditions

Advanced Solid Tumors

Interventions

DRUG

OSI-930 and erlotinib

OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity

Trial Locations (2)

H Lee Moffitt Cancer Center and Research Institute, Tampa

The Beatson West of Scotland Cancer Centre, Glasgow